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ABSTRACT
Background and aims: It has recently been described
that bradykinin B2 receptors are expressed in the human
gallbladder and that their activation induces a powerful
contraction, especially in acute cholecystitis tissues. Here
the role of the B1 receptor in the contractility of control
and inflamed human gallbladder was investigated.
Methods: Strips of human gallbladder from either acute
gallstone cholecystitis or elective gastro-entero-pancrea-
tic surgery (control) were assessed in vitro and processed
for reverse transcription-PCR analysis. Cumulative con-
centration–response curves with the selective B1 receptor
agonist, Lys-Des-Arg9-bradykinin, cholecystokinin and
carbachol were performed in control and cholecystitis
specimens.
Results: Lys-Des-Arg9-bradykinin concentration-depen-
dently contracted strips of control gallbladders and its
motor effect was higher in inflamed gallbladders. Lys-Des-
Arg9-bradykinin-induced contraction was not altered by
pretreatment with the selective bradykinin B2 receptor
antagonist, HOE140 (1 mM), the NK1 (SR140333), NK2
(SR48968) and NK3 (SR142801) tachykinin receptor
antagonists (all 1 mM), the muscarinic acetylcholine
receptor antagonist, atropine (1 mM), and the cyclo-
oxygenase inhibitor, indomethacin (5 mM). In contrast,
the Lys-Des-Arg9-bradykinin-induced motor response was
significantly reduced by the selective B1 receptor
antagonist, R-715. Finally, quantitative real-time PCR
analysis indicated that B1 receptor mRNA levels were
significantly higher in cholecystitis smooth muscle speci-
mens, when compared with that observed in control
tissues.
Conclusions: Bradykinin B1 receptor has an important
role as a spasmogen of human gallbladder, and selective
antagonists of the B1 receptor may represent a valid
therapeutic option to control pain in patients with acute
cholecystitis.
Kinins and their receptors constitute an important
biological system activated by diverse stimuli such
as inflammation and injury. Kinins mediate their
biological effects through the activation of B1 and
B2 receptors.
1 2 Des-Arg9-bradykinin and Lys-Des-
Arg9-bradykinin (Lys-DBK) show high affinity for
the B1 receptor and a low affinity for the B2
receptor, whereas the opposite happens for brady-
kinin and Lys-bradykinin (Lys-BK).1 B2 receptors
are constitutively present in a large array of cells
including smooth muscle, endothelial and epithe-
lial cells. In contrast, B1 receptors are rarely
expressed in healthy tissues and their expression
is classically promoted by inflammatory cytokines,
growth factors, bacterial toxins or following in
vitro incubation of the tissue: rabbit aorta;3 rat
urinary bladder;4 pig coronary arteries;5 bovine
mesenteric arteries;6 canine blood vessels;7 human
colon8; and mouse trachea and urinary bladder.9
Thus, in vitro exposure of tissues has been a well-
defined method to unravel responses to selective B1
receptor agonists and antagonists.
Diverse relaxant and contractile mediators reg-
ulate the motility of the human gallbladder:
vasoactive intestinal polypeptide (VIP) and nitric
oxide (NO) relax human gallbladder smooth
muscle, whereas cholecystokinin (CCK) induces
muscle contraction, at least in part, through the
activation of preganglionic parasympathetic neu-
rons.10 Bradykinin has been shown to exert a motor
function in guinea pig gallbladder.11 12 Recent
evidence from our group13 showed that bradykinin,
via B2 receptor activation, produces a robust
contraction of human gallbladder in vitro with a
potency and an efficacy similar to those of CCK
and higher than those of carbachol (CCh). Thus,
the two main mediators of the contractile response
of the human gallbladder seem to be bradykinin
and CCK through activation of the B2
13 and CCK
receptors,14 15 respectively. Spasms produced by
gallbladder smooth muscle contractions, in the
attempt to expel stones, greatly contribute to the
symptoms, particularly pain, that underline biliary
colic. However, the therapeutic outcome of biliary
colic obtained with antimuscarinic agents is often
poor.16 17 Thus, the question of whether additional
mediators may contribute to the contraction of the
human gallbladder is of importance to design novel
therapeutic strategies.
In this study, we have investigated the expres-
sion and the functional activation of the B1
receptor in human isolated normal and inflamed
gallbladders. The selective B1 receptor agonist Lys-
DBK was used and the mechanism of Lys-DBK-
induced gallbladder motor response was studied by
using a selective bradykinin B1 (R-715)
18 and B2
(HOE140) receptor antagonist, a combination of
tachykinin NK1 (SR 140333), NK2 (SR 48968) and
NK3 (SR 142801) receptor antagonists,
19–21 an
antimuscarinic agent (atropine) and a cyclooxy-
genase inhibitor (indomethacin).
MATERIALS AND METHODS
Human gallbladders
Strips (approximately 10620 mm) from the body
of human gallbladders were obtained from patients
(42–78 years) undergoing cholecystectomy.
Gallbladder
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Gallbladders were subdivided into two groups. The first
included gallbladders taken from 20 patients (12 males and 8
females, 47–78 years) during routine laparoscopic cholecystect-
omy (cholecystitis group). Major reported complaints of
patients included upper right quadrant abdominal pain, and
abdominal discomfort referred to as ‘‘spasm sensation’’ along
with nausea and vomiting. Patients were diagnosed as having
acute cholecystitis due to gallstone disease. In this group of
patients, ultrasonographic evaluation showed a thickened
gallbladder wall (18 out of 20 patients), and macroscopic
analysis, performed following surgery, demonstrated a swollen
viscus in the majority of patients (90%). The second group (7
males and 5 females; 42–75 years; control group) consisted of 12
patients whose gallbladders were removed during elective
abdominal surgery, including colonic or gastric resection, right
hepatic lobectomy and pancreatic-duodenectomy due to neo-
plastic disease. All patients gave their informed consent prior to
surgery, and the present study was approved by the Ethical
Committee of the University of Ferrara.
Organ bath studies
Twenty minutes after surgical removal, gallbladder tissues
dissected from the body of control and acute cholecystitis
groups were carefully cleaned and strips were placed in 5 ml
organ baths containing a Krebs buffer solution [(mM): NaCl
119, NaHCO3 25, KH2PO4 1.2, MgSO4 1.5, CaCl2 2.5, KCl 4.7
and glucose 11] maintained at 37uC and oxygenated (96% O2
and 4% CO2). Gallbladder specimens were connected to an
isometric force transducer (Unirecord 7050, Ugo Basile, Milano,
Italy); to record the mechanical activity, an optimal resting
tension of 1.5 g was applied.13 After an initial stabilisation
period (90 min) to test the tissue viability of control and
cholecystitis specimens, cumulative concentration–response
curves (CRCs) were performed with KCl (10–120 mM). After
an additional 90 min, CRCs with CCK (0.01 nM–3 mM), Lys-
DBK (1 nM–10 mM) and CCh (10 nM–10 mM) (first CRC) were
performed. Since specific experiments showed that the response
to Lys-DBK obtained at 6 h was not different in tissues with or
without the mucosa (data not shown), to avoid further tissue
manipulation mucosa-intact strips of the body of human
gallbladders taken from control and cholecystitis groups were
carefully cleaned and prepared as previously described.13
A supplementary CRC with CCK, Lys-DBK and CCh was
performed 3 h after the first CRC (second CRC). To define
better the mechanisms of Lys-DBK-induced motor effects in
human gallbladder, the effect of the selective B1 receptor
antagonist, R-715 (1 mM), and of the B2 receptor antagonist,
HOE140 (1 mM), were tested. In another set of experiments, the
effect of the combination of the tachykinin NK1 (SR 140333),
NK2 (SR 48968) and NK3 (SR 142801) receptor antagonists (all
1 mM), the antimuscarinic agent, atropine (1 mM), the cyclo-
oxygenase inhibitor, indomethacin (5 mM), the protein synth-
esis inhibitor, cycloheximide (100 mM), or their respective
vehicles were tested.
Finally, in order to confirm the concomitant activation of
both B1 and B2 receptors in inflamed human gallbladders, R-715
(1 mM) and HOE140 (1 mM) were tested, alone or in combina-
tion, against the contraction induced by Lys-BK. This peptide is
a B2 receptor agonist that, through the catalytic action of
endogenous carboxypeptidase, is transformed into Lys-DBK,
which binds with high affinity to the human B1 receptor. All
antagonists/blockers were added 15–45 min prior to the second
CRC performed with Lys-DBK or Lys-BK in cholecystitis group
specimens, except for cycloheximide that was maintained
throughout the entire experiment.
Quantitative real-time PCR
Gallbladder specimens were taken immediately (30–60 min)
after surgery and the mucosa layer was carefully removed. Total
RNA from the mucosa or smooth muscle tissues was isolated
using TRizol reagent (Invitrogen Corp., Carlsbad, Califonia,
USA) according to the manufacturers’ protocol. RNA samples
were treated for 1 h at 37uC with DNase I (Promega Corp.,
Madison, Wisconsin, USA) to avoid contaminant genomic
DNA. After the incubation, samples were heated to 95uC and
immediately chilled on ice for DNase I denaturation. We
performed reverse transcription using 5 mg of total pure RNA,
200 U of Moloney murine leukaemia virus reverse transcriptase
(Invitrogen Corp.), 5 mM dithiothreitol, 50 ng of random
hexamer primers (Invitrogen Corp.), 16 PCR buffer, 0.5 mM
dNTPs (Invitrogen Corp.) and 3 mM MgCl2. Reactions were
submitted to the protocol: 20uC for 10 min, 42uC for 45 min,
95uC for 5 min and 4uC for 10 min. To analyse B1 mRNA
expression, we performed real-time PCR using amounts of
cDNA varying from 0.1 mg to 0.1 pg in a 10-fold scale. We
carried out 25 ml reactions using 12.5 ml of the QuantiTect
SYBR Green PCR Master Mix (Qiagen, Montgomery County,
Maryland, USA) and 1 ml of each forward and reverse primer
(18 mM each) specific for human kinin B1 receptor mRNA
(forward 59-ACCTCAGCCTCTCGAGTTGCT-39, reverse 59-
TGGTTGGAGGATTGGAGCTCTA-39) or human b-actin
mRNA (forward 59-GGATCTTCATGAGGTAGTCAGTC-39,
reverse 59- CGAGGCCCAGAGCAAGAGAG -39). Reactions
were submitted to the following protocol: 50uC for 2 min,
95uC for 10 min, and 50 cycles of 95uC for 15 s, 60uC for 20 s
and 72uC for 30 s. At the end of the amplification, we
conducted a dissociation protocol and submitted samples to
electrophoresis in a 3% agarose gel to exclude any non-specific
amplification. Fluorescence emission was measured at the end
of each cycle. Ct values were plotted against logarithmic values
of the amount of cDNA in order to verify PCR efficiency, and
only those that fit in a linear correlation (R2 .0.95) to the
cDNA quantity were considered in the analysis. We used the 2–
DCt parameter to express the relative expression data of each
sample, taking b-actin as the endogenous control. As 2–DCt has to
be the same using different template amounts, we compared
this parameter in every cDNA quantity used in order to obtain
the experimental error. B1 receptor mRNA expression was
normalised by levels of b-actin expression within the same sample.
Reagents
CCK was obtained from Bachem (Bubendorf, Switzerland). Lys-
DBK, Lys-BK, cycloheximide, CCh, KCl, atropine and indo-
methacin were obtained from Sigma (Varese, Italy). HOE140
and R-715 were kind gifts of Dr B. Schoelkens (Aventis,
Frankfurt, Germany) and Dr D. Regoli (University of Ferrara,
Italy). SR 140333, SR 48968 and SR 142801 were kindly donated
by Dr X. Emonds-Alt (Sanofi-Synthelabo, Montpellier, France).
Agents were dissolved in Krebs buffer, except for indomethacin,
SR 140333, SR48968 and SR142801 which, at stock concentra-
tions (10 mM), were dissolved in 100% dimethylsulphoxide
(DMSO).
Statistical analysis
All data are expressed as the mean (SEM). Isometric tension
data were normalised to the area of the strips, and expressed as
Gallbladder
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mN/mm2. The maximum effect (Emax) and the potency of the
agonist, expressed as the negative logarithm of the concentra-
tion of agonist producing half-maximum response (pD2), was
obtained with an iterative curve-fitting package (Origin
Software, Microcal Software, Northampton, Massachusetts,
USA). Statistical analysis was performed by means of Student t
test. If p,0.05, the results were considered significant.
RESULTS
Contraction of isolated human gallbladder strips
Gallbladder strips that did not respond to 30 mM KCl were
considered not viable and were excluded from the present study.
In non-precontracted strips (n = 6) or in strips precontracted
with CCh (10 mM, n = 3) or KCl (120 mM, n = 4), Lys-DBK
failed to cause any measurable relaxation, whereas at the
highest concentrations it caused a contraction superimposed on
the CCh- or KCl-induced contraction (data not shown). First
and second CRCs with CCK (0.03 nM–3 mM) caused a
concentration-dependent motor response in both control and
cholecystitis isolated gallbladders strips, with similar Emax and
pD2 values (table 1). Similarly, no significant modification of
Emax and pD2 values of CCh-induced contractions were
observed in control and cholecystitis isolated gallbladder strips
in all the conditions studied (table 1). The threshold concentra-
tion for Lys-DBK to cause visible contractions of control and
inflamed gallbladder strips was 30–100 nM (fig 1). Lys-DBK
induced a motor response in control and inflamed gallbladder
strips with similar pD2 values (fig 1 and table 1). In contrast, the
maximal contractile effect (Emax value) produced by Lys-DBK in
the first and second CRC in gallbladder taken from cholecystitis
patients was significantly higher than that observed in control
tissues. In a further series of experiments, after 3 or 6 h of
incubation, Lys-DBK caused a motor response with similar pD2
and Emax values in specimens without the mucosa in inflamed
gallbladders (table 2).
No difference has been observed between Emax values of Lys-
DBK and CCh during the first CRC in control and cholecystitis
specimens. In contrast, a statistically significant difference of
two- and threefold was observed after 6 h of in vitro incubation
(table 1). In addition, pD2 and Emax values of Lys-DBK-induced
contraction of control and cholecystitis human gallbladder
strips were significantly lower than those of CCK in all
experimental conditions (table 1).
In another set of experiments, the B1 receptor antagonist, R-
715 (1 mM), significantly shifted to the right the second CRC
induced by Lys-DBK in cholecystitis specimens (fig 2), while the
bradykinin B2 receptor antagonist, HOE140 (1 mM), was with-
out effect (fig 2). The combination of the tachykinin NK1, NK2
and NK3 receptor antagonists, SR 140333, SR 48968 and SR
142801 (all 1 mM), atropine (1 mM) and indomethacin (5 mM)
did not affect the Lys-DBK-induced contraction of cholecystitis
gallbladder strips (fig 2). To confirm the co-functional expres-
sion of B1 and B2 receptors in the human inflamed gallbladder,
the inhibitory effect of R-715 or HOE140 was studied against
the prompt contractile effect induced by the B2 agonist, Lys-BK
(1 mM). The independent application of R-715 or HOE140 to
the organ bath significantly, but partially, prevented Lys-BK-
induced contraction (23% and 36% inhibition, respectively). In
contrast, the Lys-BK-induced motor response was reduced by
.70% when R-715 and HOE140 were co-administered (fig 3).
To demonstrate that the time-dependent increase in the
response of cholecystitis specimens to Lys-DBK matched the
increase in new protein synthesis, the protein synthesis
inhibitor, cycloheximide (100 mM), was used. Cycloheximide
completely prevented the time-dependent increase in the Lys-
DBK-induced motor response in control and inflamed human
Table 1 Emax and pD2 values of contraction induced by different spasmogens of isolated strips of control and
cholecystitis human gallbladder
Agonists
First CRC (3 h) Second CRC (6 h)
pD2 Emax (mN/mm
2) pD2 Emax (mN/mm
2)
Control group
CCK 7.17 (0.16) 0.46 (0.04) 7.30 (0.08) 0.47 (0.04)
Lys-DBK 6.11 (0.06) 0.04 (0.01) 5.97 (0.05) 0.18 (0.02)
CCh 5.90 (0.06) 0.10 (0.02) 5.90 (0.08) 0.12 (0.03)
Cholecystitis group
CCK 7.58 (0.11) 0.45 (0.03) 7.53 (0.18) 0.45 (0.03)
Lys-DBK 5.93 (0.06) 0.09 (0.02)* 5.95 (0.04) 0.31 (0.04)*
CCh 5.82 (0.16) 0.11 (0.02) 5.78 (0.01) 0.10 (0.03)
The maximum effect (Emax) and the concentration of agonist producing half-maximum response (pD2) were calculated on
cumulative concentration–response curves performed 3 and 6 h after the in vitro incubation of tissues.
*p,0.05 versus the respective value of the control group.
CCh, carbachol; CCK, cholecystokin; Lys-DBK, Lys-Des-Arg9-bradykinin.
Figure 1 Cumulative concentration–
response curves (CRCs) to Lys-Des-Arg9-
bradykinin in isolated strips of human
gallbladder taken from control and
cholecystitis patients. CRCs were
performed 3 (first CRC, A) and 6 h
(second CRC, B) after the in vitro
incubation. Values are the mean (SEM) of
at least eight experiments. *p,0.05 vs
the respective control; Student t test.
Gallbladder
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gallbladders after 6 h (second CRC) of in vitro incubation
compared with that observed during the first CRC. In contrast,
cycloheximide partially reduced, without reaching a statistically
significant difference, the maximum response to Lys-DBK after
3 h of in vitro incubation in both control and inflamed
specimens (fig 4).
Quantitative real-time PCR
B1 receptor mRNA levels, obtained by reverse transcription real-
time PCR, were measured in the mucosa or smooth muscle layer
from control and cholecystitis specimens taken immediately
after surgery. A low level of B1 receptor mRNA was observed in
the mucosa of control tissues (fig 5). The slightly increased
expression of the B1 receptor mRNA did not reach statistical
significance. In contrast, in the smooth muscle of cholecystitis
tissues a statistically significant, threefold increase in B1 mRNA
level was observed as compared with control tissues (fig 5).
DISCUSSION
Established evidence indicates that kinins are involved in a series
of physiological and pathological processes, such as control of
blood pressure, contraction and relaxation of smooth muscle,
the inflammatory response and induction of pain.22 Activation
of the kinin system has been demonstrated in a variety of
human inflammatory diseases, such as asthma, rheumatoid
arthritis, endotoxic shock, inflammatory bowel disease, pan-
creatitis and cystitis.23 24 The participation of kinins in the
pathophysiology of cholecystitis has been investigated by a
series of experimental approaches studying the ability of
bradykinin to induce motor responses in cat and guinea pig
gallbladders.25 26 Recently, we demonstrated that bradykinin
induces concentration-dependent contraction of isolated strips
of human gallbladders taken from control and cholecystitis
patients, an effect that was significantly reduced by the B2
receptor antagonist HOE140.13
In the present study, we showed that Lys-DBK, a kinin that
shows high affinity for the human B1 receptor, induces a
marked concentration-dependent contraction of cholecystitis
specimens with a significantly higher efficacy than that
observed in control gallbladders. In addition, after 6 h of tissue
incubation, Lys-DBK was more efficacious than CCh in
inducing gallbladder contraction in pathological tissues. In the
current study, the involvement of the B1 receptor was assayed
Table 2 Emax and pD2 values of Lys-DBK-induced contraction of isolated strips of mucosa-free cholecystitis
human gallbladder
Agonists
First CRC (3 h) Second CRC (6 h)
pD2 Emax (mN/mm
2) pD2 Emax (mN/mm
2)
Lys-DBK 5.89 (0.14) 0.08 (0.01) 6.07 (0.12) 0.29 (0.03)
The maximum effect (Emax) and the concentration of agonist producing half-maximum response (pD2) were calculated on
cumulative concentration–response curves performed 3 and 6 h after the in vitro incubation of tissues.
*p,0.05 versus the respective value of the control group.
CRC, concentration–response curve; Lys-DBK, Lys-Des-Arg9-bradykinin.
Figure 2 Effect of R-715, HOE140, SR 140333, SR 48968, SR 142801, atropine, indomethacin or their respective vehicles on the Lys-Des-Arg9-
bradykinin-induced motor responses in isolated strips of human gallbladder obtained from patients suffering from cholecystitis. Cumulative
concentration–response curves were performed 6 h after in vitro incubation. Values are the mean (SEM) of at least eight experiments. *p,0.05 vs the
respective vehicle; Student t test.
Gallbladder
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by using a selective B1 receptor antagonist, R-715, that shifted
to the right the CRC induced by Lys-DBK. In contrast, the
selective B2 receptor antagonist, HOE140, did not alter the
contractile effect of Lys-DBK.
Published data demonstrated that the degradation of brady-
kinin by endogenous carboxypeptidase may produce the weak
B1 receptor agonist, Des-Arg
9-bradykinin, that is at least 100-
fold less potent than Lys-DBK on the human B1 receptor.
27 This
may explain the lack of the ability of R-715 to inhibit the
contractile response induced by bradykinin in human gallblad-
der.13 Thus, in order to confirm better the concomitant
functional expression of both B1 and B2 receptors in inflamed
human gallbladders, the B2 receptor agonist, Lys-BK, which,
through the catalytic action of endogenous carboxypeptidase, is
transformed into Lys-DBK, a potent human B1 receptor agonist,
was used. As expected, the contraction induced by Lys-BK was
only partially prevented by the independent use of the B1
receptor antagonist, R-715, or the B2 receptor antagonist,
HOE140, whereas, the Lys-BK-induced contraction was power-
fully prevented (.70% of inhibition) when both antagonists
were co-administered. The present results together with our
previous data13 suggest that both B1 and B2 receptors appear to
be expressed in the human gallbladder. Moreover, the observa-
tion that cycloheximide remarkably prevented the B1-mediated
contractile response in both control and inflamed gallbladders
indicated that also in this organ new protein synthesis is the
underlying mechanism for the upregulation of B1 receptors.
Failure of cycloheximide to abolish completely the contractile
response to the B1 agonist in cholecystitis specimens might be
dependent on a rapid ex vivo expression of the receptor during
the collection process (30–60 min). However, a substantial part
of the cycloheximide-resistant contractile response is likely to be
due to in vivo receptor expression because in the inflamed
gallbladder.
To strengthen this hypothesis, expression of B1 receptor
mRNA was quantified by RT-PCR in the mucosa or smooth
muscle layer of control and cholecystitis gallbladder specimens
taken immediately after surgery. The high level of mRNA and
its remarkable upregulation in colecystitis in the smooth muscle
suggest that inflammation might have induced receptor expres-
sion in vivo. Thus, the present results corroborate and extend
general concepts described recently13 concerning in vitro B1
upregulation and imply that B1 receptors were upregulated
before the in vitro incubation and this upregulation most
probably depends on the inflammatory state of the tissue.
Moderate B1 receptor mRNA expression was also detected in
the mucosa, with a tendency to increase in inflamed specimens.
Although functional and biochemical findings indicate a
prominent role in the control of human gallbladder motility
Figure 3 Effect of R-715 and HOE140 (separately or co-administered)
or their respective vehicles on Lys-bradykinin (Lys-BK)-induced motor
responses in isolated strips of human gallbladder obtained from patients
suffering from cholecystitis. Each column represents the mean (SEM) of
at least five experiments. *p,0.05 vs vehicle (Veh) (one-way analysis of
variance followed by Dunnett test).
Figure 4 Effect of the protein synthesis
inhibitor, cycloheximide, on Lys-Des-Arg9-
bradykinin (10 mM)-induced maximal
contraction (Emax) in isolated strips of
human gallbladder obtained from control
patients and patients suffering from
cholecystitis. The contractile response of
Lys-Des-Arg9-bradykinin was observed 3
and 6 h after the in vitro incubation.
Cyclohexemide was maintained
throughout the entire experiment. Each
column represents the mean (SEM) for at
least five experiments. *p,0.05 vs the
respective vehicle (Veh) (one-way
analysis of variance followed by Dunnett
test).
Figure 5 Real-time PCR relative quantification of kinin B1 receptor
mRNA in mucosa or the smooth muscle layer of control and cholecystitis
gallbladders processed immediately after surgery. All data have been
normalised by the levels of b-actin expression within the same sample.
Plotted data are expressed as the mean (SEM) of specimens taken from
at least four different patients. a.u., arbitrary units. *p,0.05 vs the
respective control (one-way analysis of variance followed by Dunnett
test).
Gallbladder
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of B1 receptors expressed by the smooth muscle layer, a minor
and indirect contribution of the B1 receptor expressed in the
mucosa cannot be completely excluded.
Upregulation of the B1 receptor is an important feature of the
kinin system during inflammation since, differently from the B2
receptor, the B1 receptor causes much more prolonged intracel-
lular signals, is not desensitised and possesses high constitutive
activity.28 Thus, B1 receptor activation has been related to the
maintenance of chronic pain and inflammatory disorders. In
fact, most of the literature data indicate that B1 receptors are
upregulated by several proinflammatory stimuli, including some
cytokines and growth factors.24 Interestingly, it has been shown
that inflammation during gallbladder gallstone formation is
associated with increased interleukin (IL) 1 levels in the guinea
pig gallbladder wall.29 30 In addition, the bile of patients with
cholangitis has increased levels of the inflammatory cytokines
IL6 and tumour necrosis factor (TNF) a.31 Besides cytokines, the
expression of epidermal growth factor (EGF) and its receptor
was markedly increased in human chronic cholecystitis speci-
mens.32 It has been also demonstrated that IL1, TNFa and EGF
are capable of stimulating B1 receptor expression in several
tissues.33 Taking into account these considerations, it is
tempting to suggest that some cytokines and growth factors
(eg, IL1b, IL6, TNFa and EGF) could be involved in the
upregulation of the gallbladder B1 receptor, causing increased
contraction in inflamed gallbladder.
We have also investigated the mechanisms involved in the
contractile effect of B1 receptor activation in human gallbladder.
Some kinin actions are associated with the secondary produc-
tion of other mediators including prostanoids and tachykinins.24
However, in line with results obtained with bradykinin,13 the
contraction induced by Lys-DBK in cholecystitis gallbladders
was not altered by atropine, indomethacin or the combination
of NK1, NK2 and NK3 receptor antagonists. Thus, these results
suggest that Lys-DBK may have a direct effect on gallbladder
smooth muscle or it releases mediators other than prostaglan-
dins, tachykinins or acetylcholine. In addition, contraction of
non-vascular smooth muscle induced by a B1 agonist has been
demonstrated in several isolated preparations such as rat urinary
bladder and duodenum, rabbit urinary bladder human colon and
pig iris sphincter.1 34–36 In line with this evidence, it is possible to
suggest that Lys-DBK produces contraction of the human
gallbladder via a direct action on smooth muscle cells.
In summary, the current results expand previous data from
our group13 and reinforce the hypothesis that the kinin system
plays a major role in evoking contraction in normal and,
especially, in inflamed human gallbladders by stimulating both
the kinin B1 and B2 receptors. Activation of B1 receptors,
overexpressed during the cholecystitis state, may contribute to
the typical symptoms that underline biliary colic such as
gallbladder painful smooth muscle contractions. The present
findings also suggest that kinin B1 and B2 receptor antagonists
may represent a valuable therapeutic option to control
symptoms in patients with acute cholecystitis.
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